PointState Capital’s Biogen BIIB Stock Holding History

PointState Capital’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-40,000	Closed	-$11.3M	–	125
2021 Q3	$11.3M	Hold	40,000	–	–	0.19%	74
2021 Q2	$13.9M	Buy	+40,000	New	+$12.1M	0.24%	70
2021 Q1	–	Sell	-38,500	Closed	-$9.43M	–	124
2020 Q4	$9.43M	Buy	+38,500	New	+$9.93M	0.18%	79
2017 Q2	–	Sell	-10,000	Closed	-$2.73M	–	138
2017 Q1	$2.73M	Buy	+10,000	New	+$2.83M	0.03%	121

Other funds holding BIIB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

PointState Capital's BIIB Position: Q1 2022 in Review

PointState Capital sold out of Biogen (BIIB) in Q1 2022, closing a stake of 21,000 shares — an estimated $5.04M sold.

PointState Capital first reported a position in BIIB in Q4 2014 and held it in 18 quarters. The position peaked at $245M in Q4 2017. 953 funds tracked by Wall St. Rank hold BIIB as of Q1 2022.

PointState Capital reported no remaining Biogen position as of Q1 2022 after selling out during the quarter.
PointState Capital sold 21,000 Biogen shares in Q1 2022, an estimated $5.04M.
PointState Capital first reported a position in Biogen in Q4 2014 and held it in 18 quarters.
PointState Capital's Biogen position peaked at $245M in Q4 2017.
953 funds tracked by Wall St. Rank held Biogen as of Q1 2022.

Based on PointState Capital's 13F filing for Q1 2022, filed 13 May 2022.